

# Giorgina Specchia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3583038/publications.pdf>

Version: 2024-02-01

300  
papers

13,076  
citations

31976

53  
h-index

28297

105  
g-index

302  
all docs

302  
docs citations

302  
times ranked

13193  
citing authors

#	ARTICLE	IF	CITATIONS
1	Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia. <i>New England Journal of Medicine</i> , 2013, 369, 111-121.	27.0	1,284
2	Cardiovascular Events and Intensity of Treatment in Polycythemia Vera. <i>New England Journal of Medicine</i> , 2013, 368, 22-33.	27.0	664
3	Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia. <i>New England Journal of Medicine</i> , 2005, 353, 977-987.	27.0	571
4	Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. <i>Blood</i> , 2007, 110, 840-846.	1.4	419
5	Invasive Infections Caused by <i>Trichosporon</i> Species and <i>Geotrichum capitatum</i> in Patients with Hematological Malignancies: a Retrospective Multicenter Study from Italy and Review of the Literature. <i>Journal of Clinical Microbiology</i> , 2005, 43, 1818-1828.	3.9	347
6	Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. <i>Blood</i> , 2002, 99, 863-871.	1.4	325
7	Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. <i>Blood</i> , 2010, 116, 3171-3179.	1.4	290
8	Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. <i>Haematologica</i> , 2010, 95, 644-650.	3.5	273
9	Itraconazole Oral Solution as Prophylaxis for Fungal Infections in Neutropenic Patients with Hematologic Malignancies: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. <i>Clinical Infectious Diseases</i> , 1999, 28, 250-255.	5.8	233
10	JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. <i>Blood</i> , 2007, 110, 4030-4036.	1.4	233
11	Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. <i>Blood</i> , 2011, 118, 6153-6163.	1.4	227
12	Therapy of Molecular Relapse in Acute Promyelocytic Leukemia. <i>Blood</i> , 1999, 94, 2225-2229.	1.4	217
13	Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. <i>Blood</i> , 2008, 112, 844-847.	1.4	216
14	Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. <i>Blood</i> , 2009, 114, 1477-1483.	1.4	196
15	Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. <i>Blood</i> , 2006, 108, 1999-2005.	1.4	181
16	A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. <i>Blood</i> , 2005, 105, 3434-3441.	1.4	178
17	Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. <i>Blood</i> , 2009, 113, 4497-4504.	1.4	173
18	AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. <i>Blood</i> , 2011, 117, 4716-4725.	1.4	173

#	ARTICLE	IF	CITATIONS
19	CD56 Expression Is an Indicator of Poor Clinical Outcome in Patients With Acute Promyelocytic Leukemia Treated With Simultaneous All-Trans-Retinoic Acid and Chemotherapy. <i>Journal of Clinical Oncology</i> , 2000, 18, 1295-1300.	1.6	156
20	High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 219-228.	1.6	145
21	Extramedullary Involvement at Relapse in Acute Promyelocytic Leukemia Patients Treated or Not With All-Trans Retinoic Acid: A Report by the Gruppo Italiano Malattie Ematologiche dell'Adulto. <i>Journal of Clinical Oncology</i> , 2001, 19, 4023-4028.	1.6	135
22	BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. <i>Blood</i> , 2011, 118, 3419-3425.	1.4	123
23	Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. <i>Haematologica</i> , 2013, 98, 1702-1710.	3.5	121
24	Spontaneous remission of $\epsilon$ -methotrexate-associated lymphoproliferative disorders after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature. <i>Medical Oncology</i> , 2009, 26, 1-9.	2.5	118
25	Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. <i>Blood</i> , 2012, 120, 761-767.	1.4	110
26	A phase II study of $\epsilon$ ivinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. <i>British Journal of Haematology</i> , 2013, 161, 688-694.	2.5	109
27	Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. <i>MAbs</i> , 2013, 5, 826-837.	5.2	105
28	Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. <i>American Journal of Hematology</i> , 2014, 89, 480-486.	4.1	104
29	Vascular Endothelial Growth Factor Serum Levels Are Elevated in Patients with Hereditary Hemorrhagic Telangiectasia. <i>Acta Haematologica</i> , 2003, 110, 29-32.	1.4	100
30	CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. <i>Blood</i> , 2010, 116, 3907-3922.	1.4	100
31	Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. <i>Blood</i> , 2011, 117, 6793-6800.	1.4	98
32	Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. <i>American Journal of Hematology</i> , 2015, 90, E80-5.	4.1	93
33	A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1991, 27, 750-755.	0.7	92
34	Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: impact on WHO classification. <i>Blood</i> , 2006, 108, 4146-4155.	1.4	92
35	Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. <i>Haematologica</i> , 2008, 93, 1792-1796.	3.5	91
36	ORIGINAL ARTICLE: Abnormal Pattern of Lymphocyte Subpopulations in the Endometrium of Infertile Women with Chronic Endometritis. <i>American Journal of Reproductive Immunology</i> , 2009, 61, 322-329.	1.2	90

#	ARTICLE	IF	CITATIONS
37	Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. <i>Blood</i> , 2013, 122, 3759-3766.	1.4	82
38	Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17). <i>Journal of Clinical Oncology</i> , 2013, 31, 4424-4430.	1.6	78
39	Sclerostin is overexpressed by plasma cells from multiple myeloma patients. <i>Annals of the New York Academy of Sciences</i> , 2011, 1237, 19-23.	3.8	77
40	Randomized Phase III Trial of Retinoic Acid and Arsenic Trioxide Versus Retinoic Acid and Chemotherapy in Patients With Acute Promyelocytic Leukemia: Health-Related Quality-of-Life Outcomes. <i>Journal of Clinical Oncology</i> , 2014, 32, 3406-3412.	1.6	76
41	Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry. <i>American Journal of Hematology</i> , 2009, 84, 636-640.	4.1	75
42	The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. <i>Haematologica</i> , 2009, 94, 205-212.	3.5	73
43	The Role of Angiogenesis in Human Non-Hodgkin Lymphomas. <i>Neoplasia</i> , 2013, 15, 231-238.	5.3	70
44	Extramedullary involvement in patients with acute promyelocytic leukemia. <i>Cancer</i> , 1998, 83, 1522-1528.	4.1	66
45	Neutrophilic-chronic myeloid leukemia. <i>Cancer</i> , 2002, 94, 2416-2425.	4.1	66
46	A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. <i>Blood</i> , 2020, 136, 171-182.	1.4	65
47	Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians. <i>Haematologica</i> , 2011, 96, 696-702.	3.5	64
48	Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study). <i>Haematologica</i> , 2015, 100, 284-292.	3.5	64
49	E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features. <i>British Journal of Haematology</i> , 2003, 120, 484-487.	2.5	63
50	Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines. <i>Translational Research</i> , 2005, 145, 212-220.	2.3	60
51	Next-Generation Sequencing in Acute Lymphoblastic Leukemia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2929.	4.1	60
52	Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. <i>Blood</i> , 2009, 113, 3428-3434.	1.4	59
53	Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2015, 168, 361-370.	2.5	59
54	Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. <i>Haematologica</i> , 2011, 96, 1457-1461.	3.5	58

#	ARTICLE	IF	CITATIONS
55	Results of a Multicenter, Controlled, Randomized Clinical Trial Evaluating the Combination of Piperacillin/Tazobactam and Tigecycline in High-Risk Hematologic Patients With Cancer With Febrile Neutropenia. <i>Journal of Clinical Oncology</i> , 2014, 32, 1463-1471.	1.6	55
56	Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. <i>American Journal of Hematology</i> , 2020, 95, 156-166.	4.1	53
57	LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease. <i>Oncotarget</i> , 2014, 5, 12950-12967.	1.8	52
58	TP53 gene mutation analysis in chronic lymphocytic leukemia by nanopore MinION sequencing. <i>Diagnostic Pathology</i> , 2016, 11, 96.	2.0	51
59	The biological characteristics of CD34+ CD2+ adult acute promyelocytic leukemia and the CD34 CD2 hypergranular (M3) and microgranular (M3v) phenotypes. <i>Haematologica</i> , 2006, 91, 311-6.	3.5	51
60	Invasive Fungal Infections in Patients with Hematologic Malignancies (Aurora Project): Lights and Shadows During 18-Months Surveillance. <i>International Journal of Molecular Sciences</i> , 2012, 13, 774-787.	4.1	50
61	Breakpoint characterization of der(9) deletions in chronic myeloid leukemia patients. <i>Genes Chromosomes and Cancer</i> , 2002, 35, 271-276.	2.8	48
62	Long-Term Outcome of Complete Cytogenetic Responders After Imatinib 400 mg in Late Chronic Phase, Philadelphia-Positive Chronic Myeloid Leukemia: The GIMEMA Working Party on CML. <i>Journal of Clinical Oncology</i> , 2008, 26, 106-111.	1.6	48
63	High Ki67 Index and Bulky Disease Remain Significant Adverse Prognostic Factors in Patients with Diffuse Large B Cell Lymphoma before and after the Introduction of Rituximab. <i>Acta Haematologica</i> , 2011, 126, 44-51.	1.4	48
64	Characterization of Specific Immune Responses to Different Aspergillus Antigens during the Course of Invasive Aspergillosis in Hematologic Patients. <i>PLoS ONE</i> , 2013, 8, e74326.	2.5	48
65	Extramedullary blast crisis in chronic myeloid leukemia. <i>Leukemia Research</i> , 1996, 20, 905-908.	0.8	46
66	ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. <i>Blood</i> , 2007, 109, 5473-5476.	1.4	46
67	The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a 6-year retrospective multicenter experience of the Rete Ematologica Pugliese (REP). <i>Annals of Hematology</i> , 2016, 95, 239-244.	1.8	46
68	Normal percentage of CD56bright natural killer cells in young patients with a history of repeated unexplained implantation failure after in vitro fertilization cycles. <i>Fertility and Sterility</i> , 2007, 88, 990-993.	1.0	45
69	Microvascular density, CD68 and tryptase expression in human Diffuse Large B-Cell Lymphoma. <i>Leukemia Research</i> , 2014, 38, 1374-1377.	0.8	44
70	The response to imatinib and interferon- $\alpha$ is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. <i>Haematologica</i> , 2010, 95, 1415-1419.	3.5	43
71	Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. <i>Haematologica</i> , 2013, 98, 399-403.	3.5	42
72	Droplet Digital PCR Is a Robust Tool for Monitoring Minimal Residual Disease in Adult Philadelphia-Positive Acute Lymphoblastic Leukemia. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 474-482.	2.8	41

#	ARTICLE	IF	CITATIONS
73	New Insights into Diffuse Large B-Cell Lymphoma Pathobiology. <i>Cancers</i> , 2020, 12, 1869.	3.7	41
74	Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. <i>Blood</i> , 2014, 124, 3029-3031.	1.4	40
75	Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma. <i>Transfusion</i> , 2014, 54, 331-339.	1.6	39
76	Clinico-biologic features and treatment outcome of adult pro-B-ALL patients enrolled in the GIMEMA 0496 study: absence of the ALL1/AF4 and of the BCR/ABL fusion genes correlates with a significantly better clinical outcome. <i>Blood</i> , 2003, 102, 2014-2020.	1.4	38
77	Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements. <i>Molecular Cancer</i> , 2010, 9, 120.	19.2	37
78	Evidence of a Hypercoagulable State in Patients with Acute Lymphoblastic Leukemia Treated with Low Dose of E.coli L-Asparaginase: A GIMEMA Study. <i>Thrombosis and Haemostasis</i> , 1993, 69, 012-015.	3.4	37
79	Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life. <i>Leukemia and Lymphoma</i> , 2010, 51, 1007-1014.	1.3	36
80	Mutational analysis in BCR - ABL1 positive leukemia by deep sequencing based on nanopore MinION technology. <i>Experimental and Molecular Pathology</i> , 2017, 103, 33-37.	2.1	36
81	Identification of new partner chromosomes involved in fusions with the ETV6 (TEL) gene in hematologic malignancies. <i>Genes Chromosomes and Cancer</i> , 1998, 21, 223-229.	2.8	35
82	Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIÉS, GITMO groups. <i>Haematologica</i> , 2013, 98, 1344-1352.	3.5	35
83	Absolute quantification of the pretreatment PML-RARA transcript defines the relapse risk in acute promyelocytic leukemia. <i>Oncotarget</i> , 2015, 6, 13269-13277.	1.8	35
84	Digital PCR: A Reliable Tool for Analyzing and Monitoring Hematologic Malignancies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3141.	4.1	35
85	Autoimmune Myelofibrosis: Report of Three Cases and Review of the Literature. <i>Leukemia and Lymphoma</i> , 2004, 45, 561-566.	1.3	34
86	Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients. <i>Journal of Pathology</i> , 2013, 229, 87-98.	4.5	34
87	A multicentre observational study for early diagnosis of Gaucher disease in patients with Splenomegaly and/or Thrombocytopenia. <i>European Journal of Haematology</i> , 2016, 96, 352-359.	2.2	34
88	Droplet Digital PCR Is a Reliable Tool for Monitoring Minimal Residual Disease in Acute Promyelocytic Leukemia. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 437-444.	2.8	34
89	Design and MinION testing of a nanopore targeted gene sequencing panel for chronic lymphocytic leukemia. <i>Scientific Reports</i> , 2018, 8, 11798.	3.3	34
90	Insights in Hodgkin Lymphoma angiogenesis. <i>Leukemia Research</i> , 2014, 38, 857-861.	0.8	33

#	ARTICLE	IF	CITATIONS
91	Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia. <i>Leukemia Research</i> , 2011, 35, 1557-1563.	0.8	32
92	Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. <i>Annals of Hematology</i> , 2018, 97, 95-100.	1.8	32
93	Recovery of CMV-Specific CD8+ T Cells and Tregs after Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 550-557.	2.0	31
94	Novel <i>NPM1</i> exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML. <i>Blood</i> , 2021, 138, 2696-2701.	1.4	30
95	Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. <i>Leukemia and Lymphoma</i> , 2013, 54, 2458-2465.	1.3	29
96	Genomic BCR-ABL1 breakpoint characterization by a multi-strategy approach for personalized monitoring of residual disease in chronic myeloid leukemia patients. <i>Oncotarget</i> , 2018, 9, 10978-10986.	1.8	29
97	Inflammatory Cells in Diffuse Large B Cell Lymphoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 2418.	2.4	29
98	Nanopore Sequencing in Blood Diseases: A Wide Range of Opportunities. <i>Frontiers in Genetics</i> , 2020, 11, 76.	2.3	29
99	Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances. <i>Cancer Management and Research</i> , 2020, Volume 12, 3175-3189.	1.9	29
100	Pneumonia in Acute Leukemia Patients During Induction Therapy: Experience in a Single Institution. <i>Leukemia and Lymphoma</i> , 2003, 44, 97-101.	1.3	28
101	CD3+/Tregs Ratio in Donor Grafts Is Linked to Acute Graft-versus-Host Disease and Immunologic Recovery after Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 887-893.	2.0	27
102	SETBP1 and miR_4319 dysregulation in primary myelofibrosis progression to acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2012, 5, 48.	17.0	27
103	DDX3X-MLLT10 fusion in adults with NOTCH1 positive T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2014, 99, 64-66.	3.5	27
104	Assessment of DNA damages in lymphocytes of agricultural workers exposed to pesticides by comet assay in a cross-sectional study. <i>Biomarkers</i> , 2018, 23, 462-473.	1.9	27
105	Liquid chromatographic determination of urinary 5-methyl-2-deoxycytidine and pseudouridine as potential biological markers for leukaemia. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1999, 21, 1045-1051.	2.8	26
106	Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis. <i>American Journal of Hematology</i> , 2018, 93, E159-E161.	4.1	26
107	Nanopore Targeted Sequencing for Rapid Gene Mutations Detection in Acute Myeloid Leukemia. <i>Genes</i> , 2019, 10, 1026.	2.4	26
108	<i>SETBP1</i> dysregulation in congenital disorders and myeloid neoplasms. <i>Oncotarget</i> , 2017, 8, 51920-51935.	1.8	26

#	ARTICLE	IF	CITATIONS
109	A fluorescence in situ hybridization study of complex t(9;22) in two chronic myelocytic leukemia cases with a masked Philadelphia chromosome. <i>Cancer Genetics and Cytogenetics</i> , 2004, 150, 81-85.	1.0	25
110	Changes in <i>RPS14</i> expression levels during lenalidomide treatment in Low- and Intermediate-risk myelodysplastic syndromes with chromosome 5q deletion. <i>European Journal of Haematology</i> , 2010, 85, 231-235.	2.2	25
111	TP53 in Myelodysplastic Syndromes: Recent Biological and Clinical Findings. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3432.	4.1	25
112	Effects of prednisolone on the dystrophin-associated proteins in the blood-brain barrier and skeletal muscle of dystrophic mdx mice. <i>Laboratory Investigation</i> , 2013, 93, 592-610.	3.7	24
113	BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 467, 357-363.	2.8	24
114	Home-brew-FISH assay shows higher efficiency than BCR-ABL dual color, dual fusion probe in detecting microdeletions and complex rearrangements associated with t(9;22) in chronic myeloid leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2007, 174, 121-126.	1.0	23
115	Droplet digital PCR analysis of <i>NOTCH1</i> gene mutations in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 86469-86479.	1.8	23
116	Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine?. <i>Cancers</i> , 2020, 12, 185.	3.7	22
117	Cytochemical normal and abnormal eosinophils in acute leukemias. <i>American Journal of Hematology</i> , 1977, 2, 123-131.	4.1	21
118	Molecular cytogenetic characterization of deletions on der(9) in chronic myelocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2006, 167, 97-102.	1.0	21
119	CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?. <i>Expert Review of Hematology</i> , 2017, 10, 853-862.	2.2	21
120	Bone Involvement in Hodgkin's Lymphoma: Clinical Features and Outcome. <i>Acta Haematologica</i> , 2018, 140, 178-182.	1.4	21
121	Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome. <i>Cancers</i> , 2021, 13, 1311.	3.7	21
122	Dysregulation of miRNA in Leukemia: Exploiting miRNA Expression Profiles as Biomarkers. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7156.	4.1	21
123	Human monocyte-derived dendritic cells exposed to hyperthermia show a distinct gene expression profile and selective upregulation of <i>IGFBP6</i> . <i>Oncotarget</i> , 2017, 8, 60826-60840.	1.8	21
124	Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization. <i>Leukemia Research</i> , 2011, 35, 899-903.	0.8	20
125	LIGHT/TNFSF14 as a New Biomarker of Bone Disease in Multiple Myeloma Patients Experiencing Therapeutic Regimens. <i>Frontiers in Immunology</i> , 2018, 9, 2459.	4.8	20
126	Insertions generating the 5'RUNX1/3'CBFA2T1 gene in acute myeloid leukemia cases show variable breakpoints. <i>Genes Chromosomes and Cancer</i> , 2004, 41, 86-91.	2.8	19



#	ARTICLE	IF	CITATIONS
127	Adherence to international guidelines for the treatment of invasive aspergillosis in acute myeloid leukaemia: feasibility and utility (SEIFEM-2008B study). <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2013-2018.	3.0	19
128	Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. <i>Annals of Hematology</i> , 2012, 91, 825-835.	1.8	19
129	RARA and RARG gene downregulation associated with EZH2 mutation in acute promyelocytic-like morphology leukemia. <i>Human Pathology</i> , 2018, 80, 82-86.	2.0	19
130	STAT3, tumor microenvironment, and microvessel density in diffuse large B cell lymphomas. <i>Leukemia and Lymphoma</i> , 2020, 61, 567-574.	1.3	19
131	Lymphoid enhancer binding factor-1 (LEF1) expression as a prognostic factor in adult acute promyelocytic leukemia. <i>Oncotarget</i> , 2014, 5, 649-658.	1.8	19
132	Angiogenesis and Hereditary Hemorrhagic Telangiectasia. <i>Acta Haematologica</i> , 2001, 106, 214-219.	1.4	18
133	M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience. <i>Haematologica</i> , 2008, 93, 1025-1032.	3.5	18
134	Risk evaluation, prophylaxis, and treatment of tumor lysis syndrome: Consensus of an Italian expert panel. <i>Advances in Therapy</i> , 2011, 28, 684-697.	2.9	18
135	Outcome of Allogeneic Peripheral Blood Stem Cell Transplantation by Donor Graft CD3+/Tregs Ratio: A Single-Center Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 495-499.	2.0	18
136	RARG Gene Dysregulation in Acute Myeloid Leukemia. <i>Frontiers in Molecular Biosciences</i> , 2019, 6, 114.	3.5	18
137	Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2020, 10, 883.	2.8	18
138	ATRA and Arsenic Trioxide (ATO) Versus ATRA and Idarubicin (AIDA) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia (APL): Results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AMLSC. <i>Blood</i> , 2012, 120, 6-6.	1.4	18
139	Genomic deletions on other chromosomes involved in variant t(9;22) chronic myeloid leukemia cases. <i>Genes Chromosomes and Cancer</i> , 2003, 36, 353-360.	2.8	17
140	Derivative Chromosome 9 Deletions in Chronic Myeloid Leukemia are Associated with Loss of Tumor Suppressor Genes. <i>Leukemia and Lymphoma</i> , 2004, 45, 689-694.	1.3	17
141	Early and Long-Term Engraftment after Autologous Peripheral Stem Cell Transplantation in Acute Myeloid Leukemia Patients. <i>Acta Haematologica</i> , 2006, 116, 229-237.	1.4	17
142	Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas. <i>Advances in Hematology</i> , 2011, 2011, 1-6.	1.0	17
143	T cells, mast cells and microvascular density in diffuse large B cell lymphoma. <i>Clinical and Experimental Medicine</i> , 2016, 16, 301-306.	3.6	17
144	Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. <i>Haematologica</i> , 2020, 106, 291-294.	3.5	17

#	ARTICLE	IF	CITATIONS
145	Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP). <i>Annals of Hematology</i> , 2021, 100, 429-436.	1.8	17
146	Cytotoxic activity and mechanism of action of 5-aza-2'-deoxycytidine in human CML cells. <i>Leukemia Research</i> , 1993, 17, 977-982.	0.8	16
147	EXTRAMEDULLARY DISEASE IN ACUTE PROMYELOCYTIC LEUKEMIA: TWO-IN-ONE DISEASE. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011066.	1.3	16
148	Droplet digital PCR assay for quantifying of CALR mutant allelic burden in myeloproliferative neoplasms. <i>Annals of Hematology</i> , 2016, 95, 1559-1560.	1.8	16
149	The JAK2 GGCC (46/1) Haplotype in Myeloproliferative Neoplasms: Causal or Random?. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1152.	4.1	16
150	The Pleiotropic Role of Retinoic Acid/Retinoic Acid Receptors Signaling: From Vitamin A Metabolism to Gene Rearrangements in Acute Promyelocytic Leukemia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2921.	4.1	16
151	Feasibility of peripheral blood stem cell rescue as intensification in elderly patients with acute myelocytic leukaemia: a pilot study from the Gimema Group. <i>British Journal of Haematology</i> , 2000, 111, 334-337.	2.5	16
152	Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2016, 101, e196-e199.	3.5	15
153	Retinal Abnormalities in Newly Diagnosed Adult Acute Myeloid Leukemia. <i>Acta Haematologica</i> , 2001, 105, 197-203.	1.4	14
154	Gene expression profiling of chronic myeloid leukemia with variant t(9;22) reveals a different signature from cases with classic translocation. <i>Molecular Cancer</i> , 2013, 12, 36.	19.2	14
155	FLAG-Ida Regimen as Bridge Therapy to Allotransplantation in Refractory/Relapsed Acute Myeloid Leukemia Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 767-773.	0.4	14
156	Excellent Outcomes at 3 Years with Nilotinib 800 Mg Daily In Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML WP Clinical Trial. <i>Blood</i> , 2010, 116, 359-359.	1.4	14
157	Stat3-positive tumor cells contribute to vessels neof ormation in primary central nervous system lymphoma. <i>Oncotarget</i> , 2017, 8, 31254-31269.	1.8	14
158	Reciprocal translocation t(12;13)(p13;q14) in acute nonlymphoblastic leukemia: Report and cytogenetic analysis of two cases. <i>Cancer Genetics and Cytogenetics</i> , 1994, 77, 106-110.	1.0	13
159	Schnitzler's Syndrome: Monoclonal Gammopathy Associated with Chronic Urticaria. <i>Acta Haematologica</i> , 2008, 120, 1-4.	1.4	13
160	Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients. <i>American Journal of Hematology</i> , 2010, 85, 960-963.	4.1	13
161	Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis. <i>Leukemia Research</i> , 2014, 38, 1446-1450.	0.8	13
162	Translocation of the proto-oncogene Bcl-6 in human glioblastoma multiforme. <i>Cancer Letters</i> , 2014, 353, 41-51.	7.2	13

#	ARTICLE	IF	CITATIONS
163	Unbiased pro-thrombotic features at diagnosis in 977 thrombocytopenic patients with Philadelphia-negative chronic myeloproliferative neoplasms. <i>Leukemia Research</i> , 2016, 46, 18-25.	0.8	13
164	Risk of lymphoma subtypes by occupational exposure in Southern Italy. <i>Journal of Occupational Medicine and Toxicology</i> , 2017, 12, 31.	2.2	13
165	Monosomal karyotype in myeloid neoplasias: a literature review. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2163-2171.	2.0	13
166	Submicroscopic deletions in an acute myeloid leukemia case with a four-way t(8;11;16;21). <i>Leukemia Research</i> , 2005, 29, 855-858.	0.8	12
167	Isolation and characterization of neural stem cells from dystrophic mdx mouse. <i>Experimental Cell Research</i> , 2016, 343, 190-207.	2.6	12
168	Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients. <i>BMC Cancer</i> , 2020, 20, 1140.	2.6	12
169	Immunomodulatory Drugs in Acute Myeloid Leukemia Treatment. <i>Cancers</i> , 2020, 12, 2528.	3.7	12
170	Clonal Hematopoiesis at the Crossroads of Inflammatory Bowel Diseases and Hematological Malignancies: A Biological Link?. <i>Frontiers in Oncology</i> , 2022, 12, 873896.	2.8	12
171	Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 26, 340-342.	2.3	11
172	Concomitant Primary Polycythemia Vera and Follicle Center Cell Non-Hodgkin Lymphoma: A Case Report and Review of the Literature. <i>Leukemia and Lymphoma</i> , 2002, 43, 2217-2220.	1.3	11
173	Primary intracranial dural B cell small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 1437-1443.	1.3	11
174	5â€“RUNX1-3â€“TMUSP42 chimeric gene in acute myeloid leukemia can occur through an insertion mechanism rather than translocation and may be mediated by genomic segmental duplications. <i>Molecular Cytogenetics</i> , 2014, 7, 66.	0.9	11
175	Immunophenotypic and molecular features of â€“cuplikeâ€“ acute myeloid leukemias. <i>European Journal of Haematology</i> , 2014, 92, 121-126.	2.2	11
176	Pregnancy rate and outcome of pregnancies in long-term survivors of Hodgkinâ€™s lymphoma. <i>Annals of Hematology</i> , 2019, 98, 1947-1952.	1.8	11
177	RNAscope dual ISHâ€“IHC technology to study angiogenesis in diffuse large B-cell lymphomas. <i>Histochemistry and Cell Biology</i> , 2020, 153, 185-192.	1.7	11
178	Inflammatory Infiltrate and Angiogenesis in Mantle Cell Lymphoma. <i>Translational Oncology</i> , 2020, 13, 100744.	3.7	11
179	Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkinâ€™s lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study. <i>Bone Marrow Transplantation</i> , 2020, 55, 2114-2120.	2.4	11
180	Acute myeloid leukemia with t(16;16) (p13;q22) showing a new CFBF-MYH11 fusion transcript associated with an atypical leukemic blasts morphology. <i>Human Pathology</i> , 2014, 45, 643-647.	2.0	10

#	ARTICLE	IF	CITATIONS
181	Outcomes of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphomas: A Retrospective Multicenter Experience by the Rete Ematologica Pugliese (REP). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 35-40.	0.4	10
182	Correlation between circulating blood and microenvironment T lymphocytes in diffuse large B-cell lymphomas. <i>Journal of Clinical Pathology</i> , 2022, 75, 493-497.	2.0	10
183	Gimema Registry of Conception/Pregnancy in Adult Italian Patients Diagnosed with Chronic Myeloid Leukemia (CML): Report on 166 Outcomes. <i>Blood</i> , 2018, 132, 43-43.	1.4	10
184	Roneparstat (SST0001), an Innovative Heparanase (HPSE) Inhibitor for Multiple Myeloma (MM) Therapy: First in Man Study. <i>Blood</i> , 2015, 126, 3246-3246.	1.4	10
185	Constitutive expression of IL-1 $\beta$ , M-CSF and c-fms during the myeloid blastic phase of chronic myelogenous leukaemia. <i>British Journal of Haematology</i> , 1992, 80, 310-316.	2.5	9
186	Acute promyelocytic leukemia with additional chromosome abnormalities in a renal transplant case. <i>Annals of Hematology</i> , 2001, 80, 246-250.	1.8	9
187	Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. <i>Leukemia and Lymphoma</i> , 2009, 50, 114-118.	1.3	9
188	Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP). <i>Annals of Hematology</i> , 2018, 97, 1817-1824.	1.8	9
189	Acute lymphoblastic leukemia hand-mirror cells. <i>Blut</i> , 1983, 47, 297-306.	1.2	8
190	Aquaporin-4 expression in primary human central nervous system lymphomas correlates with tumour cell proliferation and phenotypic heterogeneity of the vessel wall. <i>European Journal of Cancer</i> , 2012, 48, 772-781.	2.8	8
191	A novel t(4;16)(q25;q23.1) associated with EGF and ELOVL6 deregulation in acute myeloid leukemia. <i>Gene</i> , 2013, 529, 144-147.	2.2	8
192	IgG-lymphoplasmacytic lymphoma following polycythemia vera: JAK2 V617F and MYD88 L265P mutations separated in the same house. <i>Annals of Hematology</i> , 2014, 93, 1605-1607.	1.8	8
193	Overexpression of the LSAMP and TUSC7 genes in acute myeloid leukemia following microdeletion/duplication of chromosome 3. <i>Cancer Genetics</i> , 2015, 208, 517-522.	0.4	8
194	Computer-driven quantitative image analysis in the assessment of tumor cell and T cell features in diffuse large B cell lymphomas. <i>Annals of Hematology</i> , 2018, 97, 663-668.	1.8	8
195	Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin's lymphoma patients. <i>Annals of Hematology</i> , 2019, 98, 1449-1455.	1.8	8
196	HMGA Proteins in Hematological Malignancies. <i>Cancers</i> , 2020, 12, 1456.	3.7	8
197	Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors. <i>Hematological Oncology</i> , 2021, 39, 401-408.	1.7	8
198	The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2018, 132, 44-44.	1.4	8

#	ARTICLE	IF	CITATIONS
199	Concomitant tetrasomy 3q and trisomy 18 in CD5 <sup>+</sup> , CD13 <sup>+</sup> chronic lymphocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2002, 133, 160-163.	1.0	7
200	A chronic myelocytic leukemia case bearing deletions on the three chromosomes involved in a variant t(9;22;11). <i>Cancer Genetics and Cytogenetics</i> , 2004, 148, 137-140.	1.0	7
201	Non-treatment-related chronic myeloid leukemia as a second malignancy. <i>Leukemia Research</i> , 2004, 28, 115-119.	0.8	7
202	<i>MIRN199B</i> downregulation in chronic myeloid leukaemia is associated with deletions on der(9). <i>British Journal of Haematology</i> , 2009, 144, 271-273.	2.5	7
203	Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2011, 86, 523-525.	4.1	7
204	A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. <i>Leukemia and Lymphoma</i> , 2011, 52, 2329-2335.	1.3	7
205	MYEOV gene overexpression in primary plasma cell leukemia with t(11;14)(q13;q32). <i>Oncology Letters</i> , 2016, 12, 1460-1464.	1.8	7
206	Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies. <i>Diagnostic Pathology</i> , 2018, 13, 98.	2.0	7
207	<p>Skin lesions in chronic myeloid leukemia patients during dasatinib treatment</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 7991-7996.	1.9	7
208	Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper. <i>Cancer Medicine</i> , 2020, 9, 2960-2970.	2.8	7
209	Long-term Hodgkin Lymphoma Survivors: A Glimpse of What Happens 10 Years After Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e506-e512.	0.4	7
210	Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial. <i>Blood</i> , 2019, 134, 3000-3000.	1.4	7
211	Hypertensive Uveitis as a Feature of Multiple Myeloma. <i>Ocular Immunology and Inflammation</i> , 2010, 18, 104-106.	1.8	6
212	A new recurrent chromosomal translocation t(3;11)(q13;q14) in myelodysplastic syndromes associated with overexpression of the ILDR1 gene. <i>Leukemia Research</i> , 2012, 36, 852-856.	0.8	6
213	ADAMTS2 gene dysregulation in T/myeloid mixed phenotype acute leukemia. <i>BMC Cancer</i> , 2014, 14, 963.	2.6	6
214	Extralymphatic Disease Is an Independent Prognostic Factor in Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e261-e266.	0.4	6
215	Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network. <i>Frontiers in Oncology</i> , 2021, 11, 739171.	2.8	6
216	Nanopore sequencing approach for immunoglobulin gene analysis in chronic lymphocytic leukemia. <i>Scientific Reports</i> , 2021, 11, 17668.	3.3	6

#	ARTICLE	IF	CITATIONS
217	Rituximab Plus Chlorambucil As Initial Treatment for Elderly Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Pre-Treatment Biological Characteristics and Gene Expression Patterns on Response to Treatment. <i>Blood</i> , 2011, 118, 294-294.	1.4	6
218	Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies. <i>Blood</i> , 2011, 118, 112-112.	1.4	6
219	Extramedullary molecular evidence of the 5â€™KIAA1509/3â€™PDGFRB fusion gene in chronic eosinophilic leukemia. <i>Leukemia Research</i> , 2008, 32, 347-351.	0.8	5
220	Peripheral blood CD4/CD19 cell ratio is an independent prognostic factor in classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 1596-1601.	1.3	5
221	Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11â€“12, 2013. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 181-189.	4.4	5
222	Absolute lymphocyte count is unrelated to overall survival in newly diagnosed elderly patients with multiple myeloma treated with immunomodulatory drugs. <i>Leukemia and Lymphoma</i> , 2015, 56, 1507-1509.	1.3	5
223	Azacitidine in the treatment of older patients affected by acute myeloid leukemia: A report by the Rete Ematologica Pugliese (REP). <i>Leukemia Research</i> , 2015, 39, 1166-1171.	0.8	5
224	Myelodysplastic syndrome with 5q deletion following IgM monoclonal gammopathy, showing gene mutation MYD88 L265P. <i>Blood Cells, Molecules, and Diseases</i> , 2015, 54, 51-52.	1.4	5
225	Erythrocytosis with JAK2 GGCC_46/1 haplotype and without JAK2 V617F mutation is associated with CALR rs1049481_G allele. <i>Leukemia</i> , 2021, 35, 619-622.	7.2	5
226	Nanopore sequencing sheds a light on the <i>FLT3</i> gene mutations complexity in acute promyelocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1219-1225.	1.3	5
227	Tumor Microenvironment and Microvascular Density in Follicular Lymphoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 1257.	2.4	5
228	Second Cancer Onset in Myeloproliferative Neoplasms: What, When, Why?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3177.	4.1	5
229	Inside the biology of early T-cell precursor acute lymphoblastic leukemia: the perfect trick. <i>Biomarker Research</i> , 2021, 9, 89.	6.8	5
230	Molecular cytogenetic study of instability at 1q21â¼q32 in adult acute lymphoblastic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2005, 156, 54-58.	1.0	4
231	Use of tyrosine kinase inhibitors in a patient with Brugada syndrome and chronic myeloid leukemia. <i>International Journal of Hematology</i> , 2013, 98, 483-486.	1.6	4
232	Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2687.	4.3	4
233	A novel t(3;9)(q21.2; p24.3) associated with SMARCA2 and ZNF148 genes rearrangement in myelodysplastic syndrome. <i>Leukemia and Lymphoma</i> , 2018, 59, 996-999.	1.3	4
234	Delayed allergy to acyclovir revealed by lymphocyte proliferation test. <i>Postepy Dermatologii i Alergologii</i> , 2018, 35, 527-529.	0.9	4

#	ARTICLE	IF	CITATIONS
235	Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials. <i>Annals of Hematology</i> , 2018, 97, 1785-1795.	1.8	4
236	Impact of Bone Marrow Aspirate Tregs on the Response Rate of Younger Newly Diagnosed Acute Myeloid Leukemia Patients. <i>Journal of Immunology Research</i> , 2018, 2018, 1-7.	2.2	4
237	Different spatial distribution of inflammatory cells in the tumor microenvironment of ABC and GBC subgroups of diffuse large B cell lymphoma. <i>Clinical and Experimental Medicine</i> , 2021, 21, 573-578.	3.6	4
238	Detection of BCR/ABL rearrangements in adult acute lymphoblastic leukemia using a highly sensitive interphase fluorescence in situ hybridization method (D-FISH). <i>The Hematology Journal</i> , 2001, 2, 54-60.	1.4	4
239	Chronic Myeloid Leukemia Italian Multicenter Observational Study (CML-IT-MOS): Clinical Characteristics of Chronic Myeloid Leukemia (CML) Patients Treated in Real-Life between 2012 and 2016 in 66 Italian Hematology Centers of the Gimema Study Group. <i>Blood</i> , 2018, 132, 45-45.	1.4	4
240	A Prospective Study of Imatinib 400 mg vs 800 mg Frontline in High Risk Ph+ Chronic Myeloid Leukemia (CML) Patients.. <i>Blood</i> , 2007, 110, 26-26.	1.4	4
241	Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse.. <i>Blood</i> , 2012, 120, 2601-2601.	1.4	4
242	FLT3 mutational analysis in acute myeloid leukemia: Advantages and pitfalls with different approaches. <i>Blood Reviews</i> , 2022, 54, 100928.	5.7	4
243	A novel translocation t(2;9)(q14;p12) in AML-M2 with an uncommon phenotype: myeloperoxidase-positive and myeloid antigen-negative. <i>Leukemia Research</i> , 2001, 25, 501-507.	0.8	3
244	Molecular cytogenetic characterization of a novel additional chromosomal aberration in blast crisis of a Ph-positive chronic myeloid leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2002, 134, 109-113.	1.0	3
245	CT-guided needle biopsy performed with modified coaxial technique in patients with refractory or recurrent lymphomas. <i>Annals of Hematology</i> , 2014, 93, 1559-1564.	1.8	3
246	A desensitization protocol for delayed allergy to cytarabine: analysis of two cases. <i>Postepy Dermatologii i Alergologii</i> , 2018, 35, 222-224.	0.9	3
247	Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study. <i>Leukemia</i> , 2021, 35, 1814-1816.	7.2	3
248	The Impact of Graft CD3 Cell/Regulatory T Cell Ratio on Acute Graft-versus-Host Disease and Post-Transplantation Outcome: A Prospective Multicenter Study of Patients with Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 918.e1-918.e9.	1.2	3
249	Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.. <i>Blood</i> , 2009, 114, 860-860.	1.4	3
250	A Large-Scale Trial Testing the Intensity of Cyto-reductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera (CYTO-PV trial). <i>Blood</i> , 2012, 120, 4-4.	1.4	3
251	Imatinib High Dose (800 mg): Results of a Phase II Trial of the GIMEMA (Gruppo Italiano Malattie Tumorali) Trial. <i>Journal of Clinical Oncology</i> , 2006, 24, 7843-7850.	1.4	3
251	Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients.. <i>Blood</i> , 2006, 108, 4776-4776.	1.4	3
252	Long-Term Follow-Up of Elderly Patients with Acute Myeloid Leukemia Treated with Decitabine: A Real-World Study of the Apulian Hematological Network. <i>Cancers</i> , 2022, 14, 826.	3.7	3

#	ARTICLE	IF	CITATIONS
253	The Effect of the Tumor Microenvironment on Lymphoid Neoplasms Derived from B Cells. <i>Diagnostics</i> , 2022, 12, 573.	2.6	3
254	IRF4 expression is low in Philadelphia negative myeloproliferative neoplasms and is associated with a worse prognosis. <i>Experimental Hematology and Oncology</i> , 2021, 10, 58.	5.0	3
255	Doxorubicin and m-AMSA induced DNA damage in blast cells from AML patients. <i>Leukemia Research</i> , 1991, 15, 19-24.	0.8	2
256	Idarubicin plus Cytosine-Arabinoside (ALL R-87 Protocol) in Advanced Acute Lymphoblastic Leukemia: The GIMEMA/AIEOP Experience. <i>Leukemia and Lymphoma</i> , 1992, 7, 15-18.	1.3	2
257	Familial clustering of HTLV-I infection in southeastern Italy. <i>Lancet, The</i> , 1995, 346, 179-180.	13.7	2
258	<i>JAK2&lt;/i&gt;V617F mutation persists in blasts and mature cells of transformed <i>JAK2&lt;/i&gt;V617Fâ€positiveâ€myeloproliferative neoplasia: A European leukemia net (ENL) study. <i>American Journal of Hematology</i>, 2010, 85, 383-386.</i></i>	4.1	2
259	BCL6 corepressor gene dysregulation due to chromosomal translocation in acute myeloid leukemia: a new mechanism based on long non-coding RNA dislocation?. <i>Leukemia and Lymphoma</i> , 2014, 55, 2199-2201.	1.3	2
260	In male Hodgkin lymphoma patients, impaired fertility may be improved by nonâ€gonadotoxic therapy. <i>British Journal of Haematology</i> , 2022, 196, 110-115.	2.5	2
261	Can the New and Old Drugs Exert an Immunomodulatory Effect in Acute Myeloid Leukemia?. <i>Cancers</i> , 2021, 13, 4121.	3.7	2
262	Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkinâ€™s lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation. <i>Supportive Care in Cancer</i> , 2022, 30, 1521-1527.	2.2	2
263	In Early-Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib, Resistance Is Rarely Mediated by Abl Kinase Domain Mutations.. <i>Blood</i> , 2007, 110, 1934-1934.	1.4	2
264	BCR-ABL Fusion Transcript Do Not Significantly Influence the Outcome of Chronic Myeloid Leukemia Patients In Early Chronic Phase Treated with Imatinib Mesylate: a GIMEMA CML WP Analysis.. <i>Blood</i> , 2010, 116, 1230-1230.	1.4	2
265	Prognostic Impact of t(4;11)(q21;q23)/KMT2A-AFF1-Positivity in 926 BCR-ABL1-Negative B-Lineage Acute Lymphoblastic Leukemia Patients Treated in Gimema Clinical Trials Since 1996. <i>Blood</i> , 2019, 134, 1469-1469.	1.4	2
266	Single-Cell Sequencing: Ariadneâ€™s Thread in the Maze of Acute Myeloid Leukemia. <i>Diagnostics</i> , 2022, 12, 996.	2.6	2
267	Molecular cytogenetics characterization of a novel translocation involving chromosomes 17 and 19 in a Ph+ adult acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2002, 119, 488-491.	2.5	1
268	The double deceit generated by an insertion mechanism in chronic myeloid leukemia with t(9;9;22). <i>Annals of Hematology</i> , 2008, 87, 923-926.	1.8	1
269	National Italian Delphi panel consensus: which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia?. <i>BMC Cancer</i> , 2020, 20, 956.	2.6	1
270	Neutrophilicâ€chronic myeloid leukemia. <i>Cancer</i> , 2002, 94, 2416-2425.	4.1	1



#	ARTICLE	IF	CITATIONS
271	Determinants of Choice of Front-Line Tyrosine Kinase Inhibitor for Chronic Phase CML: A Study from the "Registro Italiano LMC & Campus CML". <i>Blood</i> , 2020, 136, 35-36.	1.4	1
272	Deletions of the Derivative Chromosome 9 Do Not Influence Response to Imatinib of Early Chronic Phase Chronic Myeloid Leukemia Patients (A GIMEMA Working Party Analysis).. <i>Blood</i> , 2006, 108, 2112-2112.	1.4	1
273	Evidence for CD34+ Hematopoietic Progenitor Cell Involvement in Acute Myeloid Leukemia with NPM1 Gene Mutation: Implications for the Cell of Origin. <i>Blood</i> , 2008, 112, 307-307.	1.4	1
274	How Epidemiology of Polycythemia Vera Has Changed in the Last 10 Years: Results From the Whole Prospective Cohort of Patients in Cyto-PV Trial As Compared with Eclap Prospective Cohort. <i>Blood</i> , 2012, 120, 1748-1748.	1.4	1
275	Droplet Digital PCR Analysis for Diagnosis and Minimal Residual Disease Monitoring in Adult Ph+ Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 4989-4989.	1.4	1
276	Quality of Life Scores Have a Prognostic Significance In Elderly AML Patients.. <i>Blood</i> , 2008, 112, 1949-1949.	1.4	1
277	Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph+-CML. <i>Blood</i> , 2014, 124, 1794-1794.	1.4	1
278	Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study. <i>Blood</i> , 2020, 136, 45-46.	1.4	1
279	Evaluation of leukemic contamination in peripheral blood stem cell leukaphereses vs bone marrow after consolidation therapy in acute myeloid leukemia: not a critical factor in outcome?. <i>Haematologica</i> , 2003, 88, 715-8.	3.5	1
280	A novel translocation t(14;15)(q32;q24) bearing deletion on der(14) in Philadelphia-positive chronic myeloid leukemia. <i>Haematologica</i> , 2003, 88, 1076-7.	3.5	1
281	Clonal hematopoiesis in clinical practice: walking a tightrope. <i>Leukemia and Lymphoma</i> , 2022, 63, 2536-2544.	1.3	1
282	Molecular cytogenetic findings supporting the evidence of a biclonal origin in acute myeloid leukemia. <i>Annals of Hematology</i> , 2006, 85, 129-131.	1.8	0
283	Computed tomography-guided needle biopsy performed with modified coaxial technique in patients with suspected lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 1949-1951.	1.3	0
284	A complex and cryptic intrachromosomal rearrangement generating the FIP1L1_PDGFR $\alpha$ in adult acute myeloid leukemia. <i>Cancer Genetics</i> , 2019, 239, 8-12.	0.4	0
285	Health technology assessmentâ€based approach to flow cytometric immunophenotyping of acute leukemias: a literature classification. <i>Tumori</i> , 2020, 106, 249-256.	1.1	0
286	Management of patients with acute myeloid leukemia undergoing therapy with midostaurin: a focus on antifungal prophylaxis. <i>Hematological Oncology</i> , 2021, 39, 20-26.	1.7	0
287	Hypereosinophilia with a pinch of salt and pepper. <i>EJHaem</i> , 2021, 2, 665-666.	1.0	0
288	Heterogeneous Chromosomal Mechanisms Generating the 5â€RUNX1/3â€CBFA2T1 Gene in Acute Myeloid Leukemia.. <i>Blood</i> , 2004, 104, 4272-4272.	1.4	0

#	ARTICLE	IF	CITATIONS
289	Chromosome 9 and 22 Breakpoints Cluster Regions Definition of Deleted Sequences on der(9) in Chronic Myeloid Leukemia.. Blood, 2005, 106, 4842-4842.	1.4	0
290	Phase II Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy. Blood, 2008, 112, 4288-4288.	1.4	0
291	Cytoreductive Therapeutic Approach in the Essential Thrombocythemia (ET) Patients of the Registro Italiano Trombocitemia (RIT): Preliminary Data. Blood, 2008, 112, 5248-5248.	1.4	0
292	One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (â%¥ 65 years) Ph+ CML Patients â€“ EudraCT Number 2007â€“005102-42, ClinicalTrials.Gov NCT 00858806.. Blood, 2010, 116, 3412-3412.	1.4	0
293	Fatigue Is the Major Aspect Compromising Health-Related Quality of Life of Chronic Myeloid Leukemia Patients Receiving Long-Term Imatinib Therapy. Blood, 2012, 120, 4234-4234.	1.4	0
294	Patients with Unexplained Thrombosis Require a Prompt Investigation to Search a Chronic Myeloproliferative Neoplasm (MPN), Even If Platelet Count Is < 600x109/L. Analysis on 129 Patients from Registro Italiano Trombocitemie (RIT). Blood, 2015, 126, 5181-5181.	1.4	0
295	Clinical and Biological Features in Patients with Ph-Negative Chronic Myeloproliferative Neoplasm Showing Different Molecular Pattern. Comparative Study in 596 Patients of the Registro Italiano Trombocitemie (RIT). Blood, 2015, 126, 4071-4071.	1.4	0
296	Real Life Evaluation of Efficacy and Safety of Bosutinib Therapy in Chronic Myeloid Leukemia Patients. Blood, 2018, 132, 3021-3021.	1.4	0
297	Droplet Digital PCR for the Quantification of Alu Methylation Status in Hematological Malignancies. Blood, 2018, 132, 2612-2612.	1.4	0
298	Phase II Multicenter, Not Comparative, Study of Multiple Doses of NEPA (netupitant + palonosetron) in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Non-Hodgkin Lymphoma Patients Eligible for Autologous Hematopoietic Stem Cell Transplantation Receiving Multiple Days / High Dose Chemotherapy Regimens. Blood, 2019, 134, 1974-1974.	1.4	0
299	Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study. Blood, 2020, 136, 47-48.	1.4	0
300	A Crumbled but Fatal Acute Leukemia. Turkish Journal of Haematology, 2022, 39, 76-77.	0.5	0